ANTI CANCER

Imugene gains guidance for KEY-Vaxx Immunotherapy development

Finfeed Archived Mar 21, 2019

Imugene Limited (ASX:IMU) has now received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy.

First patient dosed in phase 2 trial with Imugene’s gastric cancer vaccine

Finfeed Archived Mar 14, 2019

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced dosing of the first patient in a in 68 patient randomised Phase 2 HER-Vaxx cancer trial.

Imugene to present cancer vaccine programs to the American Association for Cancer Research

Finfeed Archived Mar 04, 2019

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on its KEYVaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Cashed up Imugene to present at American Association for Cancer Research

Finfeed Archived Feb 28, 2019

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Next Investors Archived Jan 31, 2019

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

PTX is one step closer to finding a working cancer treatment

Finfeed Archived Jan 29, 2019

Prescient Therapeutics (ASX:PTX) CEO Steven Yatomi-Clarke speaks with Finfeed about the latest results in the company's cancer treatment trials.

Imugene's promising trial results: five patients with >30% decrease in tumour size

Finfeed Archived Dec 17, 2018

Imugene (ASX:IMU) has met all study endpoints and produced positive top-line results from its Phase 1b study of its HER-Vaxx gastric cancer vaccine.

Imugene Meets All Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial

Next Investors Archived Dec 17, 2018

Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

Rhythm moves into next growth phase, appoints new CEO

Finfeed Archived Nov 28, 2018

Medical diagnostics pioneer, Rhythm Biosciences (ASX: RHY), has made some senior management changes, appointing Glenn Gilbert as its CEO, effective immediately.

Anti Cancer